Trump threatens 100% tariffs on drugmakers who aren't building U.S. plants
Summary
President Trump announced plans to impose a 100% tariff on imported branded drugs made by companies that have not started building manufacturing plants in the U.S. by October 1. This move is intended to encourage pharmaceutical companies to increase manufacturing in the U.S. Several major drug companies have already committed to investing in U.S. manufacturing facilities.Key Facts
- President Trump plans to impose 100% tariffs on imported branded drugs if companies do not start U.S. manufacturing by October 1.
- Tariffs on drugs could increase to 150% in a year-and-a-half, and possibly reach 250%.
- Some major drug companies, like Eli Lilly and AstraZeneca, have committed to building U.S. facilities.
- The drug industry opposes the tariffs and suggests alternative measures like favorable tax policies.
- U.S.-bound imports of branded drugs from Europe will face a 15% tariff under a recent trade deal.
- Europe is a major supplier of branded drugs to the U.S., with Ireland accounting for $50 billion of U.S. imports last year.
- The pharmaceutical industry argues that money spent on tariffs could reduce investment in U.S. manufacturing and drug development.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.